Skip to main content
. 2016 Aug 1;11(8):e0160388. doi: 10.1371/journal.pone.0160388

Fig 4. A subset of anti-mMDTCS mAbs inhibit plasma mADAMTS13 activity.

Fig 4

The effect of anti-mADAMTS13 mAbs on the proteolytic activity of plasma mADAMTS13 was tested in vitro using the FRETS-VWF73 assay. (A) All anti-mADAMTS13 mAbs, both anti-mMDTCS and anti-mT2-CUB2 mAbs, were tested. For each condition, the activity of plasma mADAMTS13 was calculated using a calibration curve of 2.5%, 5%, 10% and 15% NMP. (B) Time profile of the cleavage of the FRETS-VWF73 substrate by plasma mADAMTS13, in the absence or presence of mAbs 13B4 and/or 14H7. Error bars represent the SD of at least three independently performed experiments.